Introduction
Sleep disturbance often leads to physical and psychological distress, including fatigue and sleepiness in the daytime, which can interfere with the ability of patients to function normally, and contributes to a decline in quality of life [1] . It is particularly important to alleviate stress for terminal cancer patients as much as possible by ensuring sufficient quality and quantity of sleep.
Intravenous administration of benzodiazepines is suitable for patients who cannot take oral medications due to gastrointestinal cancer or other cancers in head and neck, and for patients who do not sufficiently respond to oral or per-rectal benzodiazepine preparations. In Japan midazolam has been empirically administered to ensure nighttime sleep in many palliative care units; nevertheless, optimal doses and other parameters for administration have not been established [2] .
Midazolam produces a hypnotic and sedative effect and is commonly used as an anesthetic induction agent and as an intravenous agent for sedation in the ICU [3] [4] [5] [6] [7] [8] [9] . In the field of palliative medicine, midazolam has been administered by continuous infusion intravenously or subcutaneously to ease terminal uncontrollable symptoms such as delirium, nausea and vomiting, dyspnea, and fatigue [10] [11] [12] .
When midazolam is used as an agent for nocturnal sedation both sufficient nighttime sleep and arousal upon awakening the next day must be ensured. Midazolam appears to be suitable for administration by continuous infusion for nocturnal sedation, because it has be characterized by relatively rapid onset of action and short recovery time. While it is possible that tolerance may develop during continuous long-term use of midazolam [4, [10] [11] [12] , it has not been reported, as far as we know, whether tolerance develops during repeated intermittent short-term infusion for insomnia. In the present study, patients with terminal cancer treated with midazolam infusion were retrospectively surveyed to assess the optimal infusion rates of midazolam needed to maintain appropriate sleep without oversedation and with clear arousal on the following morning.
Statistical analysis was conducted to analyze time-dependent changes in maintenance doses and possible associated factors.
Materials and methods
The study examined the clinical response of 19 patients (mean , Hiroyasu Ogata
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Sleep disturbance often leads to physical and psychological distress and contributes to poor quality of life in terminal cancer patients. Midazolam is administered by continuous intravenous infusion in many Japanese palliative care units for the purpose of nocturnal sedation when patients cannot take oral medications or do not sufficiently respond to oral or per-rectal medication. However, there is insufficient data to assess optimal doses and other parameters for administration. In addition, the possibility of tolerance to midazolam reported in several studies is a further limitation. The present study retrospectively surveyed inpatient hospice experience in 19 patients who were prescribed midazolam in an attempt to induce nocturnal sedation. The midazolam infusion rate used for the longest period each day to maintain appropriate sleep without oversadation and with clear arousal on the following morning was defined as the "maintenance dose". The infusion rate was adjusted by bedside nurses who monitored the patients' vital signs and sedation levels at 1 or 2 hour intervals during the night. The rate was adjusted to maintain a sedation level of 3 to 5 (according to Ramsey's sedation scale [13] ), at which the patients did not respond to slight stimuli, from the induction of sleep to midnight, and a sedation level of 2 to 3, at which the patients respond to slight stimuli, in the early morning.
The infusion rate of midazolam that was used for the longest period each day and resulted in appropriate sleep for each patient was defined as the "maintenance dose".
Statistical analysis
Changes in the maintenance doses over time were analyzed by a mixed-effects model using NONMEM software (Version V level 1.0; Globomax LLC, MD, USA).
Time dependency of the changes in maintenance doses was examined using 2 models: one was a model which assumed that maintenance doses were constant irrespective of time (Y=θ1), and the other model assumed that maintenance doses changed with time in a linear manner (Y=θ2t+θ1). The deviances (log likelihood)
calculated for the two models were then compared.
We next examined the influence of age, dose of opioids administered, serum creatinine level, serum ALT level, gender, haloperidol administration, ketamine administration, dyspnea, bone metastasis and pain on maintenance doses.
The representative dose of opioids administered was based on the maximum dose in the study period for each patient and was expressed in relation to an equivalent dose of morphine. Fentanyl patch (25μg/h) and 50 mg/day oral morphine were defined as the equivalent of 25 mg/day parenterally administered morphine [14] .
Results Figure 1 shows the change in the infusion rate of midazolam in patient 9 from the day 1 to the day 2. While maintaining the patient in an appropriate sedative condition (level 3 to 5 according to Ramsey's sedation scale), the infusion rate was sequentially decreased, and the rate was maintained to achieve light sedative condition (level 2 to 3) in the early morning. The infusion rate at which midazolam was infused for the longest period from the night to the morning was defined as the "maintenance dose" for that resulted in an appropriate sleep condition. Table   3 , demonstrated that the maintenance dose was significantly greater in patients treated with haloperidol than in patients not treated with haloperidol (p<0.005).
Discussion
Physical and psychological distress caused by sleep disturbance make the patients' last days unbearable; therefore, sleep of sufficient quality and quantity is important for these patients. The remaining 17 patients were also used for the analysis of factors affecting the maintenance dose. Age was not a covariate. It has been reported that in the ICU the dose [15] and infusion rate [9] decrease with age when the sedation level is kept at the same level for all patients, and it has also been reported that pharmacological reactivity to hypnotics increases in aged people [9, 16] . However, an age-dependent decrease in the maintenance dose was not observed in this study, probably because the subjects were relatively old and relatively less varied in age (46 -94 years of age), or because the pharmacokinetic capacity varied widely among the subjects due to their varied disease conditions.
It has been reported that the dose of morphine administered after surgery can be reduced when midazolam is coadministered [3, 6] . We found that the dose of opioids was not a covariate, although it did vary widely among subjects, as shown in Table 1 This is assumed to be attributable to the pharmacological action of haloperidol and the pathological condition of patients given haloperidol. It has previously been shown, based on studies in animals, that haloperidol interacts with GABA A receptors [17] , which could affect the pharmacological action of benzodiazepines.
A possible pathological factor is the strong physical and mental suffering of terminal cancer patients treated with haloperidol for pain, nausea and delirium. Haloperidol was given to relieve these symptoms, but it appeared that it might not have been sufficiently effective. It is also possible that organic neuropsychological changes in the patients might affect the maintenance dose.
The study subjects were patients with terminal cancer whose average survival time was 24.6 ± 12.7 days. Midazolam treatment for nocturnal sedation was suff iciently safe and effective in these patients without problems from respiratory suppression or withdrawal, although a slight carry-over of the hypnotic effect was observed. In addition, an abrupt increase in the dose of midazolam did not occur in most of the patients. Midazolam infusion only in the nighttime provides sufficient sleep for patients, so that they may be able to spend their remaining days in comfort while eliminating or delaying the need for terminal sedation. Furthermore, this method is also useful for safely introducing continuous sedation because daytime midazolam infusion can be gradually combined with nighttime infusion.
Some limitation of this study should be mentioned. This was an observational study of a small number of patients, thus the result of statistical analysis have to be dealt with cautiously.
Also the maintenance dose might vary as adjusting the infusion rate and visiting intervals to the patients were left to the discretion of the nursing staff. There is a clear need for additional trials of investigating the most safe and effective way to use midazolam for nocturnal sedation.
In conclusion, the records of 19 terminal cancer patients treated with midazolam by continuous intravenous infusion for induction of nocturnal sedation were surveyed. A rapid increase in the maintenance dose was observed in 2 patients. Among the other 17 patients, the maintenance doses analyzed using NONMEM software were statistically constant over time within the investigation period. 
